We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

134 hedge funds and large institutions have $334M invested in Karyopharm Therapeutics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 58 increasing their positions, 34 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 34

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.17% less ownership

Funds ownership: 5.24% → 5.07% (-0.17%)

12% less funds holding

Funds holding: 153 → 134 (-19)

45% less capital invested

Capital invested by funds: $608M → $334M (-$273M)

58% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 33

72% less call options, than puts

Call options by funds: $2.28M | Put options by funds: $8.13M

Holders
134
Holders Change
-19
Holders Change %
-12.42%
% of All Funds
2.35%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
58
Reduced
34
Closed
33
Calls
$2.28M
Puts
$8.13M
Net Calls
-$5.85M
Net Calls Change
+$3.66M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$15.2M
2
Renaissance Technologies
Renaissance Technologies
New York
+$3.3M
3
UBS Group
UBS Group
Switzerland
+$2.18M
4
Two Sigma Investments
Two Sigma Investments
New York
+$1.73M
5
Morgan Stanley
Morgan Stanley
New York
+$1.73M

Top Sellers

Rank Fund Capital Flow
1
HRCM
Hood River Capital Management
Florida
-$8.28M
2
GIM
Granahan Investment Management
Massachusetts
-$7.55M
3
JGC
J. Goldman & Co
New York
-$6.56M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$6.15M
5
RCMNY
Rubric Capital Management (New York)
New York
-$6.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
GEA
126
Glen Eagle Advisors
New Jersey
$3.49K -$727 -7 -15%
BCA
127
Berman Capital Advisors
Georgia
$3K +$4.46K +43 New
DFCM
128
Dark Forest Capital Management
Puerto Rico
$2K +$2.91K +28 New
KFS
129
Kelly Financial Services
Massachusetts
$1.46K -$16.1K -155 -90%
AF
130
Allworth Financial
California
$1K – – –
Daiwa Securities Group
131
Daiwa Securities Group
Japan
$1K – – –
QCG
132
Quadrant Capital Group
Ohio
$1K +$415 +4 +200%
QT
133
Quantbot Technologies
New York
$1K +$2.18K +21 New
Nisa Investment Advisors
134
Nisa Investment Advisors
Missouri
$5 – – –
HRCM
135
Hood River Capital Management
Florida
– -$8.28M -53,483 Closed
GIM
136
Granahan Investment Management
Massachusetts
– -$7.55M -48,771 Closed
Wellington Management Group
137
Wellington Management Group
Massachusetts
– -$6.15M -39,733 Closed
AAM
138
AMI Asset Management
California
– -$5.31M -34,273 Closed
MOACM
139
Mutual of America Capital Management
New York
– -$2.25M -14,568 Closed
IHAM
140
Integral Health Asset Management
New York
– -$1.55M -10,000 Closed
Millennium Management
141
Millennium Management
New York
– -$1.19M -7,668 Closed
Jacobs Levy Equity Management
142
Jacobs Levy Equity Management
New Jersey
– -$839K -5,417 Closed
JF
143
Jump Financial
Illinois
– -$725K -4,686 Closed
MGIM
144
M&G Investment Management
United Kingdom
– -$622 -4,146 Closed
LCM
145
Laurion Capital Management
New York
– -$627K -4,052 Closed
Squarepoint
146
Squarepoint
New York
– -$355K -2,294 Closed
SEI Investments
147
SEI Investments
Pennsylvania
– -$314K -2,054 Closed
SCM
148
Symons Capital Management
Pennsylvania
– -$225K -1,451 Closed
CC
149
Centiva Capital
New York
– -$211K -1,360 Closed
VF
150
Virtu Financial
New York
– -$188K -1,215 Closed
3 4 5
6
7

KPTI Hedge Fund Activity: Q3 2021 in Review

134 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2021, worth a combined $334M — down 45% from $608M a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of KPTI and 14 opened new positions — a net loss of 19 holders — while 34 trimmed existing stakes and 58 added.

The largest buyer was State Street, adding an estimated $15.2M. The largest seller was Hood River Capital Management, exiting entirely with an estimated $8.28M sold.

  • 134 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2021, down from 153 in Q2 2021.
  • Funds reported $334M of Karyopharm Therapeutics stock for Q3 2021, down 45% quarter-over-quarter.
  • 14 funds opened new Karyopharm Therapeutics positions in Q3 2021 and 33 closed out, a net change of -19 holders.
  • The largest Karyopharm Therapeutics buyer in Q3 2021 was State Street, an estimated $15.2M added.
  • The largest Karyopharm Therapeutics seller in Q3 2021 was Hood River Capital Management, an estimated $8.28M sold.

Based on aggregated 13F filings for Q3 2021.